Welcome to our dedicated page for NOVARTIS SEC filings (Ticker: NVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOVARTIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOVARTIS's regulatory disclosures and financial reporting.
A holder of the issuer’s American Depositary Shares has filed a notice of planned resale under Rule 144. The filing covers 30,743 American Depositary Shares, with an aggregate market value of 4,960,276.69, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/12/2026. These shares were acquired on 01/29/2026 via restricted stock vesting as compensation from the issuer. The filing notes that shares of the same class outstanding total 1,908,151,679.
An affiliate of the issuer has filed a notice of proposed sale covering 7500 American Depositary Shares, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/09/2026 and an aggregate market value of 1171575.75.
The securities relate to a larger base of 1908151679 shares outstanding. The 7500 shares were acquired on 01/29/2026 via restricted stock vesting from the issuer as compensation, and this notice confirms the holder’s representation that they are not aware of undisclosed material adverse information about the issuer.
Novartis furnished a report on Form 6-K that provides investors with access to its latest annual information. The filing submits the Novartis Annual Report 2025 and the Report on Nonfinancial Matters 2025 as exhibits, making these documents officially available under U.S. securities law for foreign private issuers.
Novartis reported solid 2025 results with higher sales, profits and cash generation. Full‑year net sales reached USD 54.5 billion, up 8% at constant currencies, driven by strong volume growth partly offset by generic competition and pricing pressure.
Profitability improved meaningfully. Operating income rose to USD 17.6 billion (up 21%), while core operating income increased to USD 21.9 billion, lifting the core margin to 40.1% of net sales. Free cash flow was USD 17.6 billion, up 8%.
Key growth brands such as Kisqali, Kesimpta, Pluvicto, Cosentyx and Scemblix delivered strong double‑digit growth, and the pipeline advanced with new approvals and positive Phase III results in oncology, immunology and rare diseases. The Board proposes a dividend of CHF 3.70 per share, a 5.7% increase, and continued large share repurchases reduced shares outstanding by 66.9 million, contributing to a 22% rise in EPS to USD 7.21.
Novartis AG files its Form 20-F annual report describing its global pharmaceuticals business, 2025 performance context, and extensive risk profile. The company reports using IFRS in US dollars and had 1 908 151 679 ordinary shares outstanding as of year-end.
The report highlights strategic risks from global pricing and reimbursement pressure, including US measures such as the Inflation Reduction Act and “maximum fair price” agreements, and notes the loss of US exclusivity for Entresto in July 2025. It stresses dependence on successful R&D, protection of intellectual property, and competitive product launches.
Novartis discusses recent acquisitions (including Anthos Therapeutics, Regulus Therapeutics and Tourmaline Bio) and integration risks, as well as challenges in implementing AI, major IT programs, and managing cybersecurity, data privacy and complex supply chains. The company discloses USD 27.9 billion of non-current financial debt and USD 5.6 billion of current financial debt, and outlines exposure to geopolitical, macroeconomic, climate, tax and regulatory changes.
Novartis AG announced that the US FDA has approved Itvisma (onasemnogene abeparvovec-brve), the first and only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed SMN1 gene mutation. Itvisma delivers a one-time, fixed intrathecal dose that does not need to be adjusted for age or body weight and is designed to replace the missing or defective SMN1 gene.
The approval is supported by Phase III STEER and Phase IIIb STRENGTH studies, where Itvisma showed statistically significant improvement and stabilization in motor function over 52 weeks with a safety profile consistent across both trials. The therapy is intended to reduce reliance on chronic SMA treatments and will be available in the US in December, with Novartis offering patient support services to assist with access and insurance navigation.
Novartis AG updated its medium-term outlook, projecting a 5-6% constant-currency sales CAGR for 2025-2030, supported by strong existing products and a broad pipeline. Peak sales guidance was raised for key cancer drugs, with Kisqali lifted from USD 8 billion+ to USD 10 billion+ and Scemblix from USD 3 billion+ to USD 4 billion+.
The company now counts eight de‑risked, in‑market assets each targeting USD 3-10 billion in peak sales and expects 15+ potentially submission‑enabling clinical readouts over the next two years. Novartis reported a core operating income margin of 41.2% for the first nine months of 2025 and aims to sustain 40%+ margins by 2029 while absorbing dilution from its planned acquisition of Avidity Biosciences, which is expected to close in the first half of 2026, subject to conditions.
Novartis AG filed a Form 6-K reporting the issuance by Novartis Capital Corporation of multiple U.S. dollar notes, with related documents incorporated into an existing Form F-3. The tranches include: $800,000,000 Floating Rate Notes due 2028, $700,000,000 3.900% Notes due 2028, $1,750,000,000 4.100% Notes due 2030, $925,000,000 4.300% Notes due 2032, $925,000,000 4.600% Notes due 2035, $350,000,000 5.200% Notes due 2045, and $550,000,000 5.300% Notes due 2055.
The filing lists the terms agreement, forms of guaranteed debt securities, an officer’s certificate, and legal opinions to support the issuance and their inclusion in the shelf registration.
Novartis Capital Corporation, fully guaranteed by Novartis AG, launched a multi‑tranche U.S. dollar notes offering. The deal includes $800,000,000 floating‑rate notes due November 5, 2028, plus fixed‑rate tranches of $700,000,000 at 3.900% due 2028, $1,750,000,000 at 4.100% due 2030, $925,000,000 at 4.300% due 2032, $925,000,000 at 4.600% due 2035, $350,000,000 at 5.200% due 2045, and $550,000,000 at 5.300% due 2055.
The floating‑rate notes pay Compounded SOFR plus 0.52% with quarterly payments starting February 5, 2026; fixed‑rate tranches pay semiannually each May 5 and November 5, commencing May 5, 2026. The notes are senior unsecured, pari passu with the issuer’s other senior debt, and the guarantees rank equally with Novartis AG’s other senior unsecured obligations.
Estimated net proceeds are about $5,959.3 million, intended for general corporate purposes outside Switzerland, including refinancing of existing long‑ and short‑term debt. Fixed‑rate notes may be redeemed at the issuer’s option as described, and all series include tax‑related redemption provisions. The notes will not be listed, and settlement via DTC, Clearstream, and Euroclear is expected on or about November 5, 2025.